Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
14.60
+0.51 (3.62%)
Dec 5, 2025, 4:00 PM EST - Market closed
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Enanta Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $20.4, which forecasts a 39.73% increase in the stock price over the next year. The lowest target is $12 and the highest is $28.
Price Target: $20.4 (+39.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 3 | 3 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 5 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $17 | Buy | Initiates | $17 | +16.44% | Nov 14, 2025 |
| WestPark Capital | WestPark Capital | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | +91.78% | Sep 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $20 → $12 | Buy | Maintains | $20 → $12 | -17.81% | Sep 15, 2025 |
| WestPark Capital | WestPark Capital | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +64.38% | Sep 2, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $24 → $25 | Buy | Maintains | $24 → $25 | +71.23% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
65.97M
from 65.32M
Increased by 0.99%
Revenue Next Year
66.10M
from 65.97M
Increased by 0.19%
EPS This Year
-3.10
from -3.84
EPS Next Year
-2.55
from -3.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 74.4M | 80.9M | |||
| Avg | 66.0M | 66.1M | |||
| Low | 57.3M | 53.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 14.0% | 22.6% | |||
| Avg | 1.0% | 0.2% | |||
| Low | -12.2% | -18.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.29 | -1.51 | |||
| Avg | -3.10 | -2.55 | |||
| Low | -4.38 | -3.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.